APP and Alzheimer disease: Reported dose-related changes in CSF levels for APP fragments and magnitude and direction of change from baseline were also consistent with the atabecestat mode of action, which inhibits cleavage of APP by β-secretase confirmed in the early-stage AD patient populations studied here.